Event-Driven Stocks

BioCardia, Inc.

BCDANasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 3 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$0$58,000$477,000$1.4M$1.0M$145,000
Operating income−$8.3M−$8.0M−$11.6M−$11.9M−$12.6M−$15.5M
Net income−$8.2M−$7.9M−$11.6M−$11.9M−$12.6M−$15.0M
Total assets$3.4M$3.7M$3.0M$9.8M$15.7M$23.4M
Total liabilities$2.5M$2.9M$4.6M$4.9M$5.3M$4.2M
Equity$895,000$837,000−$1.6M$4.9M$10.4M$19.2M
EPS (diluted)$-1.23$-2.90$-8.19$-0.67$-0.75—
Shares out.4.7M26.7M20.2M16.9M16.3M6.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−919.3%
Return on assets
−241.1%
Return on capital (ROCE)
−843.8%
Liabilities / assets
73.8%
Debt / equity
2.81×
Book value / share
$0.19
Revenue growth (YoY)
−100.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-176.15distress
Accruals / assets
−23.2%clean
Piotroski F-Score
3/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
43
/ 100
Profitability 0Growth 0Catalyst 100Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 2 severe● 3 warning● 1 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
12 acquisitions0 disposals9 open-market buy(s)net +225,942 shares · last 12
InsiderDateTypeSharesPrice
Altman PeterOfficer — President and CEOMay 19, 2026Buy200$0.95
Altman PeterOfficer — President and CEOMay 18, 2026Buy5,700$0.92
Altman PeterOfficer — President and CEOMay 15, 2026Buy5,100$1.02
Altman PeterOfficer — President and CEOApr 29, 2026Buy5,000$1.11
Altman PeterOfficer — President and CEOApr 20, 2026Buy600$1.23
Altman PeterOfficer — President and CEOMar 24, 2026Buy600$1.24
Altman PeterOfficer — President and CEOFeb 4, 2026Buy5,000$1.13
Altman PeterOfficer — President and CEOJan 20, 2026Buy600$1.32
Altman PeterOfficer — President and CEODec 16, 2025Buy200$1.37
Altman PeterOfficer — President and CEODec 8, 2025Grant106,588$1.37
Mcclung DavidOfficer — Chief Financial OfficerDec 8, 2025Grant58,276$1.37
Gillis Edward MOfficer — Senior Vice President, DevicesDec 8, 2025Grant38,078$1.37

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026245,7751.0+48.2%
Apr 30, 2026165,8162.7-6.1%
Apr 15, 2026176,5602.8-0.4%
Mar 31, 2026177,3422.9-7.8%
Mar 13, 2026192,2572.5-11.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.